Jan 172025
In 2024, EMA recommended 114 medicines, including 46 with new active substances. Key advancements include treatments for early Alzheimer’s, von Hippel-Lindau tumors, severe infections, and innovative vaccines for Chikungunya and RSV. Cancer remained the top therapeutic focus with 28 oncology recommendations, alongside 28 new biosimilars improving access to critical therapies. EMA continues monitoring medicines post-approval to ensure safety and efficacy.
Download the report here.
Sorry, the comment form is closed at this time.